this sounds like it's different from the other anti-PD-1 agents that were discussed.
Thanks for posting this, ssflxl.
I wish they'd just get on with it! The research, I mean ...
Anti-PD-L1 is related to anti-PD1, blocking a different place in the same general pathway. There's plenty of reason to be hopeful about the agents against this target as well as nivolumab (BMS-936558) and other anti-PD1 agents in development. I'm sure that the companies are incentivized to move forward as quickly as they can, and investigators are certainly eager to participate in these trials when they can.
Dr. Howard (Jack) West
Associate Clinical Professor
City of Hope Cancer Center
Founder & President
Global Resource for Advancing
Following up on that, at the ASCO conference earlier this month there was some early data on an experimental anti-PD-L1 drug MPDL3280A that looked surprisingly good (80% odds) for patients whose cancer expressed the PD-L1 target. (I'm always looking for anything well-targeted that is effective.) That seems better than the anti-PD1's, and seems "too good" so I can't help but want to go back and re-view the details more carefully when I can. Dr. West hosted that session, so he might be in an especially good position to size up for us which approaches and specific drugs from that session really seemed most promising.
Craig in PA
Stage 4 ROS1+ [mucinous BAC] adenocarcinoma NSCLC since 2011
Xalkori (crizotinib) 5 yrs
Alimta (pemetrexed) + carboplatin (mere months)
TPX-0005 (repotrectinib) TBD (1+ years as of Fall 2018)
Will follow-up with a post on this sometime soon.